Lucid DiagnosticsLUCD -1.41%26 Quick Ratio is 1.05 as of Mar. 2026, which is 14% below its 10-year median of 1.22. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 75.06% on this metric.
Lucid Diagnostics has a quick ratio of 1.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lucid Diagnostics's Quick Ratio or its related term are showing as below:
LUCD'
s Quick Ratio Range Over the Past 10 Years
Min: 0.04 Med: 1.22 Max: 13.34
Current: 1.05
During the past 7 years, Lucid Diagnostics's highest Quick Ratio was 13.34. The lowest was 0.04. And the median was 1.22.
LUCD's Quick Ratio is ranked worse than 75.06% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs LUCD: 1.05
Lucid Diagnostics (NAS:LUCD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lucid Diagnostics Quick Ratio Related Terms
Lucid Diagnostics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lucid Diagnostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lucid Diagnostics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Quick Ratio of 1.05 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lucid Diagnostics and its competitors. This is 14% below median its historical median of 1.22. Over the past decade, Lucid Diagnostics' Quick Ratio has ranged from 0.04 to 13.34. According to the industry distribution chart, Lucid Diagnostics ranks #641 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 75.1%.
Is Lucid Diagnostics' Quick Ratio too high?
Lucid Diagnostics' current Quick Ratio of 1.05 is 14% below median its 10-year median of 1.22. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 13.34. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Lucid Diagnostics' value of 1.05 is 43.7% below this industry median. Based on the distribution chart, Lucid Diagnostics ranks #641 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Quick Ratio compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #641 out of 854 companies for Quick Ratio. This places Lucid Diagnostics in the lower half of its industry. The industry median Quick Ratio is 1.87. Lucid Diagnostics' value of 1.05 is 43.7% below this benchmark. Historically, Lucid Diagnostics' own Quick Ratio has ranged from 0.04 to 13.34 over the past decade. While the company's 10-year median is 1.22 vs. the industry median of 1.87, Lucid Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Quick Ratio of 1.05 is 43.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Quick Ratio is 1.05, which is 14% below median its own 10-year median of 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.05 — trading 29.6% above its estimated fair value. The current Quick Ratio is 1.05, which is 14% below median its 10-year median of 1.22 and 43.7% below the Medical Devices & Instruments industry median of 1.87. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Quick Ratio is 1.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.05 is trading 29.6% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Quick Ratio: 1.05 (14% below median its 10-year median of 1.22)
GF Value™: $0.81 vs. price of $1.05 (29.6% above fair value)
Industry Position: 43.7% below the Medical Devices & Instruments median (#641 of 854)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
